Definition of the initial immunologic modifications upon in vitro gliadin challenge in the small intestine of celiac patients.

Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.

Definition of the initial immunologic modifications upon in vitro gliadin challenge in the small intestine of celiac patients.

Gastroenterology. 1996 May;110(5):1368-78. Unique Identifier : AIDSLINE MED/96200520
Maiuri L; Picarelli A; Boirivant M; Coletta S; Mazzilli MC; De Vincenzi M; Londei M; Auricchio S; Children's Hospital Pausilipon, Naples, Italy.

Abstract: BACKGROUND & AIMS: Mucosal cell-mediated immune response is considered the central event in the pathogenesis of celiac disease. In cultured intestinal explants from celiacs in remission, we have characterized the early stages of gliadin-induced immune activation. METHODS: Intestinal biopsy specimens (15 treated celiacs and 13 controls) were cultured with gliadin or maize prolamine digests for 24 hours as well as for 1, 2, 4, 6, 8, and 12 hours in some subjects. The expression of immunologic markers was detected by immunocytochemistry. RESULTS: Gliadin challenge may initiate two parallel pathways, one of which leads to T-cell activation and another that precedes it. Epithelial cells overexpress DR molecules after 1 hour, and in a second stage T lymphocytes become fully activated. Moreover, T lymphocytes migrate in the upper mucosal layers. T lymphocytes that migrate in the higher lamina propria compartments are mainly CD4+ and show markers of activation; migrating intraepithelial lymphocytes are CD8+ and do not express these markers. CONCLUSIONS: In vitro gliadin challenge is a suitable model to reproduce various immunologic features of celiac lesions; these may be caused by different pathways. The comprehension of these phenomena is essential to clarify the distinctive pathogenic mechanisms leading to disease and may help in defining novel therapeutic approaches.

Keywords: Antigens, CD3/METABOLISM Celiac Disease/GENETICS/*IMMUNOLOGY CD4-Positive T-Lymphocytes/IMMUNOLOGY CD8-Positive T-Lymphocytes/IMMUNOLOGY Genotype Gliadin/*IMMUNOLOGY Human HLA Antigens/GENETICS Intestinal Mucosa/IMMUNOLOGY Intestine, Small/*IMMUNOLOGY Lymphocyte Transformation T-Lymphocytes/IMMUNOLOGY Tissue Culture JOURNAL ARTICLE
960830
M9681058

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .